Medannex Ltd
PrivateLast Round
Grant
May 11, 2026
Total Funding Raised
$15.77M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Medannex Ltd operates in Healthcare & Life Sciences and is based in Edinburgh. Its latest recorded funding round was a Grant round in May 2026.
Medannex Ltd is a biotechnology company that develops novel monoclonal antibody therapeutics to treat cancers and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Medannex Ltd Comparables
Compare Medannex Ltd with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Netris Pharma | 90% | |
| Cantargia AB | 79% | |
| F-star Therapeutics | 79% |
For institutional investors. Book with your work email.
Medannex Ltd Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 11, 2026 | ||||
| Grant | Jul 25, 2024 | ||||
| Series B | Aug 17, 2020 | ||||
| Grant | Jan 1, 2019 | ||||
| Grant | Jun 12, 2018 | ||||
Seed | Aug 28, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Medannex Ltd Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Morningside Ventures | Series B |
| Innovate UK | Grant |
| Morningside Group | Series B |
| Scottish Investment Bank (Scottish Enterprise) | Series B, Seed, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors grew 102% MoM.
- May 11, 2026
$130K grant received from Scottish Investment Bank
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 23, 2026
Medannex presents updated clinical data from the ATTAINMENT study of MDX-124 at the ESMO Congress 2026 in Spain on Oct 23rd '26.
For institutional investors. Book with your work email.
Medannex Ltd Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Medannex Ltd's valuation, stock price, and market status.
Is Medannex Ltd a public or private company?
Medannex Ltd is a private company.
What is the current stock price of Medannex Ltd?
Medannex Ltd is a private company, so its shares have no public market price. Caplight tracks Medannex Ltd's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Medannex Ltd worth (valuation)?
Valuation information for Medannex Ltd is not publicly available.
Can I buy Medannex Ltd stock?
Medannex Ltd shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Medannex Ltd's last funding round?
Medannex Ltd's most recent funding round was Grant on May 11, 2026.
Who are the main investors in Medannex Ltd?
Key investors in Medannex Ltd include Morningside Ventures, Morningside Group.
Will Medannex Ltd IPO soon?
No public IPO plans have been announced for Medannex Ltd.
How can I track Medannex Ltd secondary market activity?
Caplight tracks bids, offers, and trades in Medannex Ltd's shares on secondary markets.